About Michael Brush

Author Archive | Michael Brush

Here’s why the odds of a pullback are rising, and how to prepare for it now

Hey investors and traders, it’s time to override your emotions and get cautious on the markets. Otherwise, you might get laid low by a sharp pullback. The stock market is much more vulnerable to one now. Crowd sentiment is very bullish and insiders are quite cautious. This is not a good combination. Here’s more detail. […]

Continue Reading Comments { 0 }

Five key investing rules and a market outlook from a money manager who crushes the market

MarketWatch gives me the great opportunity to regularly interview smart people about the stock market and learn some key investing lessons. How do I know who the smart players are? After all, the stock market attracts a lot of hucksters, mediocre people, and grifters. For mutual fund managers, I apply what I call the Morningstar […]

Continue Reading Comments { 0 }

Here’s why the energy sector move is only just getting started

Energy stocks are on fire. But this move is just getting started. They could be up another 50% a year from now, in the “melt up” scenario I foresee for the economy. I don’t know what they will do tomorrow or next week, but any weakness is an opportunity to add. Here are six reasons […]

Continue Reading Comments { 0 }

Here’s a simple* way to reduce your cancer risk by a third

I spend about 20% of my time researching cancer therapy companies. I’ve done quite well investing in them. In my stock letter, I’ve suggested many 5-20 baggers. As my subscribers know, I have a multifactor model that is good at finding the winners in biotech. I expect many more winners in cancer therapy. About five […]

Continue Reading Comments { 0 }

Here’s why value investing is about to stage a big come back over growth: 20 stocks to favor in this trend

It’s because no matter who wins the election, more government spending is likely. This favors value over growth because it creates more growth and inflation. This favors value stocks for four reasons. 1) Inflation drives investors out of bonds and into perceived inflation trades — like value stocks and commodities. Larry McDonald at the Bear […]

Continue Reading Comments { 0 }

Follow MarketWatch columnist Michael Brush on Social Media

Michael Brush regularly adds market and stock commentary on social media. Please note, you need to click through the headline above to display the links below. Follow him on Twitter here. Follow him on Facebook here.

Continue Reading Comments { 0 }

This common Baker Brothers biotech investing mistake will kill your portfolio

Around two decades ago, I introduced the world to the amazing record of the Baker Brothers in biotech. Up until then, no one had written about them. Literally. The only thing I could find online when researching that column was news of their wedding announcements. But I’ve always closely studied which managers and insiders have […]

Continue Reading Comments { 0 }

How to spot a biotech takeover candidate

It’s takeover season again in biotech, and this has been great news for me and my subscribers. So far this fall, six of my favorite biotech names in my stock letter have been bought out for nice gains: Medicines Company (MDCO), Dova Pharmaceuticals, Genomic Health, Audentes Therapeutics (BOLD), Alder BioPharmaceuticals (ALDR) and Achillion Pharmaceuticals (ACHN). […]

Continue Reading Comments { 0 }

Here’s why biotech continues higher from here

Biotech has been a great performer since I suggested it as a contrarian play on October 11-12 in my MarketWatch column and in my newsletter here. * The SPDR S&P Biotech fund (XBI) is up 22.8%, and the iShares NASDAQ Biotechnology Index (IBB) has advanced 19.8%. The S&P 500 is only up 6.4%. * The […]

Continue Reading Comments { 0 }

Are we about to see a biotech takeover binge?

Kite Pharma (KITE) was a Brush Up on Stocks stock suggestion singled out in early May, 2017 because it came up very strong in my system for selecting biotech names. Gilead Sciences (GILD) liked it too. It announced plans to buy the company for cash in late August . My subscribers are now up 150% […]

Continue Reading Comments { 0 }